Real-World Clinical Outcomes in Patients Initiating Covalent Btki (cBTKi) with and without Incident Cardiovascular Adverse Events By Line of Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

被引：0

作者：

Dingli, David ^{[1
]}

De Nigris, Enrico ^{[2
]}

Leng, Siyang ^{[3
]}

Farooqui, Mohammed Z. H. ^{[3
]}

Yapici, Halit O. ^{[4
]}

Weimer, Ian ^{[4
]}

Jiao, Weiqi ^{[4
]}

Hyatt, Hayden W. ^{[4
]}

Zhang, Xuan ^{[4
]}

Lodaya, Kunal ^{[4
]}

Obeng-Kusi, Mavis ^{[3
]}

机构：

[1] Mayo Clin, Div Hematopathol, Rochester, MN USA

[2] MSD UK Ltd, London, England

[3] Merck & Co Inc, Rahway, NJ USA

[4] Boston Strateg Partners, Boston, MA USA

来源：

关键词：

D O I：

10.1182/blood-2024-198469

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3722 / 3723

页数：2